Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: A systematic review and meta-analysis.
Pancreatic cancer
exocrine pancreatic insufficiency
malnutrition
prevalence
survival
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
8
7
2020
medline:
13
7
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Pancreatic cancer is the fourth leading cause of cancer mortality. Most patients are diagnosed with advanced pancreatic cancer, either at locally advanced or metastatic stages, and have a high rate of malnutrition and weight loss which are associated with poor outcomes. Pancreatic exocrine insufficiency is one of the causes of malnutrition and weight loss in these patients. The prevalence and clinical consequences of pancreatic exocrine insufficiency in advanced pancreatic cancer are poorly investigated with heterogeneous results. We sought to determine the prevalence and clinical consequences of pancreatic exocrine insufficiency and the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer by systematic review and meta-analysis. Scopus, Medline, and Embase were searched for cohort studies or randomised clinical trials reporting pancreatic exocrine insufficiency and/or the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer. We considered pancreatic exocrine insufficiency as an abnormal result on direct and/or indirect pancreatic exocrine function tests. Pancreatic enzyme replacement therapy was evaluated by its effect on survival and quality of life in patients with advanced pancreatic cancer. A total of 11 studies were included; seven studies reported the prevalence of pancreatic exocrine insufficiency and seven the effect of pancreatic enzyme replacement therapy in advanced pancreatic cancer. The pooled prevalence of pancreatic exocrine insufficiency in advanced pancreatic cancer was 72% (95% confidence interval: 55-86%), being significantly higher when tumours were located in the pancreatic head (relative risk = 3.36, 1.07-10.54;
Sections du résumé
BACKGROUND
Pancreatic cancer is the fourth leading cause of cancer mortality. Most patients are diagnosed with advanced pancreatic cancer, either at locally advanced or metastatic stages, and have a high rate of malnutrition and weight loss which are associated with poor outcomes. Pancreatic exocrine insufficiency is one of the causes of malnutrition and weight loss in these patients. The prevalence and clinical consequences of pancreatic exocrine insufficiency in advanced pancreatic cancer are poorly investigated with heterogeneous results. We sought to determine the prevalence and clinical consequences of pancreatic exocrine insufficiency and the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer by systematic review and meta-analysis.
METHODS
Scopus, Medline, and Embase were searched for cohort studies or randomised clinical trials reporting pancreatic exocrine insufficiency and/or the effect of pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer. We considered pancreatic exocrine insufficiency as an abnormal result on direct and/or indirect pancreatic exocrine function tests. Pancreatic enzyme replacement therapy was evaluated by its effect on survival and quality of life in patients with advanced pancreatic cancer.
RESULTS
A total of 11 studies were included; seven studies reported the prevalence of pancreatic exocrine insufficiency and seven the effect of pancreatic enzyme replacement therapy in advanced pancreatic cancer. The pooled prevalence of pancreatic exocrine insufficiency in advanced pancreatic cancer was 72% (95% confidence interval: 55-86%), being significantly higher when tumours were located in the pancreatic head (relative risk = 3.36, 1.07-10.54;
Identifiants
pubmed: 32631175
doi: 10.1177/2050640620938987
pmc: PMC7724551
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1115-1125Références
Lancet. 2015 Mar 28;385(9974):1206-18
pubmed: 25479696
Cancers (Basel). 2019 Oct 26;11(11):
pubmed: 31717736
Palliat Care. 2019 Feb 17;12:1178224218825270
pubmed: 30799929
Pancreas. 2016 Mar;45(3):325-30
pubmed: 26495777
J Gastrointest Oncol. 2017 Aug;8(4):710-720
pubmed: 28890822
Nutrients. 2019 May 22;11(5):
pubmed: 31121926
BMJ Support Palliat Care. 2016 Mar;6(1):75-9
pubmed: 25164613
Cancer. 1983 Jul 15;52(2):346-52
pubmed: 6305473
Gut. 1998 Jan;42(1):92-6
pubmed: 9505892
Pancreas. 2018 Apr;47(4):e15-e16
pubmed: 29521945
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Gastroenterol Res Pract. 2017;2017:6193765
pubmed: 28912804
Gut. 2017 Aug;66(8):1354-1355
pubmed: 27941156
Aliment Pharmacol Ther. 2020 May;51(10):958-967
pubmed: 32249970
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Aliment Pharmacol Ther. 2003 Mar 15;17(6):733-50
pubmed: 12641496
Pancreas. 2017 Mar;46(3):341-346
pubmed: 28099252
Pancreatology. 2019 Jan;19(1):114-121
pubmed: 30385188
Ann Surg. 2016 Dec;264(6):949-958
pubmed: 27045859
BMC Cancer. 2018 May 5;18(1):534
pubmed: 29728096
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979186
Nutrients. 2017 Feb 23;9(3):
pubmed: 28241470
Support Care Cancer. 2017 Jun;25(6):1963-1971
pubmed: 28161789
Pancreas. 2018 Aug;47(7):800-806
pubmed: 29851751
Support Care Cancer. 2013 Jul;21(7):1835-41
pubmed: 23397095
J Clin Gastroenterol. 2014 May-Jun;48(5):e43-6
pubmed: 24717227
Pancreatology. 2016 Nov - Dec;16(6):1099-1105
pubmed: 27618657
Nutrients. 2017 Mar 07;9(3):
pubmed: 28272344
Dig Liver Dis. 2012 Nov;44(11):945-51
pubmed: 22749648
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120